Breakthrough innovations are difficult to create; yet they are critical to long term competitive advantage. This highlights the considerable opportunities and risks that face corporate entrepreneurs. We study the complex explorative and exploitative entrepreneurial processes of multinational...

We study the effect of the intellectual property rights (IPR) regime of a host country (South) on a multinational's decision between serving a market via greenfield foreign direct investment to avoid the exposure of its technology or entering a joint venture (JV) with a local firm, which allows...

We have examined all the US patents (444) issued to homegrown Indian pharma and pharma biotech firms. Most (425, 95%) patents are pharma patents not biotech (19). Also, only 11 patents have been cited ten times or more. This data provides one snapshot of the biotech industry in India today. It...

The Federal Trade Commission's 2003 innovation report revealed an interesting fact: the pharmaceutical industry is largely satisfied with today's patent system while the electronics, software and Internet industries are not. This article suggests that a difference in governing law accounts for...

There are several determinants that could have an effect on in-licensing decisions by a pharmaceutical or biotech firm. This work studies over 200 licensing deals involving big pharma companies in the period (2011 – 2015) and identifies different factors that could play a role in licensing...